Korro Bio (KRRO) has reported its FY 2025 numbers with Q4 revenue of US$1.3 million, a basic EPS loss of US$5.32 and a net income loss of US$50.0 million. Its trailing 12 month figures show revenue of US$6.4 million and a basic EPS loss of US$12.48 tied to a net loss of US$117.3 million. Over recent quarters the company has seen revenue move from US$2.3 million in Q4 FY 2024 to between US$1.1 million and US$2.6 million across FY 2025. This has come alongside quarterly basic EPS losses ranging from about US$1.92 to US$5.32. For investors, a key focus is whether the current margin pressure reflects a normal part of the company’s cost structure or indicates that expenses are weighing more heavily on the business.

See our full analysis for Korro Bio.

With the headline numbers on the table, the next step is to compare these results with the prevailing Korro Bio narratives to see which stories the data supports and which ones appear less consistent with the reported figures.

Losses widen to US$117.3 million over the year

• On a trailing 12 month basis, Korro Bio booked a net loss of US$117.3 million and a basic EPS loss of US$12.48, compared with quarterly net losses in FY 2025 that ranged from US$18.1 million in Q3 to US$50.0 million in Q4.
• Bears highlight that losses have grown at about 22.2% per year over the past five years and argue this pattern, together with forecasts for earnings to decline about 9.8% per year over the next three years, signals continued pressure on the bottom line.
  • That view lines up with the FY 2025 run rate, where every quarter shows a sizeable loss and the trailing 12 month net loss of US$117.3 million is well above any single quarter.
  • With basic EPS at a loss of US$12.48 over the past year versus quarterly EPS losses between about US$1.92 and US$5.32 in FY 2025, skeptics see little evidence of earnings stabilising in the figures provided.

On numbers like these, skeptics argue the key question is not whether Korro Bio is loss making but how long that pattern persists and what it means for future dilution risks. 🐻 Korro Bio Bear Case

Revenue base remains small at US$6.4 million

• Trailing 12 month revenue sits at US$6.4 million, built from quarterly revenue between US$1.1 million and US$2.6 million across FY 2025 and US$0 to US$2.3 million in the earlier FY 2024 quarters.
• What stands out for cautious investors is the combination of this modest revenue base with forecasts that revenue is expected to decline on average by about 45.8% per year over the next three years, which challenges any bullish view built around near term top line expansion.
  • The FY 2025 pattern already shows revenue moving within a relatively tight band, with no quarter in the data breaking out far above US$2.6 million, so there is limited support in these numbers for rapid scaling.
  • Against that backdrop, the fact that trailing revenue of US$6.4 million sits alongside a trailing net loss of US$117.3 million reinforces the idea that the current revenue mix does not yet offset the company’s cost base.

High P/S multiple with recent shareholder dilution

• The stock trades on a P/S of 28.9x, compared with 7.6x for peers and 11.6x for the wider US Biotechs group, and this sits alongside substantial shareholder dilution reported over the past year.
• Critics argue that paying almost 29x sales for a company that is unprofitable, expected to remain loss making for at least the next three years, and has already diluted shareholders heavily, sets a high bar for future execution.
  • The valuation gap is clear when you set the 28.9x P/S against the peer group at 7.6x and the broader industry at 11.6x. This means investors are currently assigning a much higher sales multiple than the averages.
  • With trailing 12 month revenue of US$6.4 million and a trailing net loss of US$117.3 million, bears question whether the premium P/S multiple can be justified without a shift in either revenue scale or the loss profile.

For a fuller picture of how these valuation and dilution themes fit into the broader story, it can help to see what other investors are focusing on right now. 📊 Read the what the Community is saying about Korro Bio.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Korro Bio's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this all sounds cautious, that is exactly why it is worth checking the facts for yourself and forming your own view quickly. To round out the picture before you decide what these numbers mean for you, take a moment to review the 3 important warning signs.

See What Else Is Out There

Korro Bio is carrying a small revenue base of US$6.4 million against a trailing net loss of US$117.3 million, with ongoing quarterly EPS losses.

If you are uneasy about those persistent losses and the premium P/S multiple, take a few minutes to check out 68 resilient stocks with low risk scores that focus on more resilient profiles and potentially steadier return paths.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.